(24/7 MARKET NEWS) – Aditxt, Inc. (NASDAQ: ADTX) shares are gaining in this morning’s premarket, at $0.225, up $0.065 (+40.69%), on 4.7 million shares traded.
Aditxt reported successful completion of a toxicology study that indicates the safety profile of ADI™-100, the Company’s immunotherapeutic technology drug that addresses rejection of transplanted organs, skin allografting, autoimmune diseases and allergies.
Aditxt, Inc. Successfully Completes Preclinical Toxicity Study of Its Psoriasis Drug Candidate ADI™-100 Advancing it Closer to First-in-Human Trials
RICHMOND, Va.–(BUSINESS WIRE)–Jul 8, 2022– Aditxt, Inc. (Nasdaq: ADTX) (“Aditxt” or the “Company”), a biotech innovation company developing and commercializing technologies focused on monitoring and reprogramming the immune system, today announces that its therapeutic program Adimune™, has successfully completed a toxicology study that indicates the safety profile of ADI™-100, the Company’s immunotherapeutic technology drug that addresses rejection of transplanted organs, skin allografting, autoimmune diseases and allergies.
